Thoracolumbar Spine Devices Industry Growth, Trends And Forecast Till 2025 By Marketresearchfuture.Com

 Market Highlights

Thoracolumbar Spine Devices Market is expected to register a CAGR of3.72% during the forecast period, with a market value of USD 8,484.7 Million till 2025. The human spinal cord, based on anatomy, is divided into three sections, namely cervical, thoracic, and lumbar. The cervical section is located at the beginning of the skull comprising of the first seven vertebrae. The thoracic spine is the midback consisting of the next 12 vertebrae, and the section from ribs to sacrum comprises the lumbar section consisting of the five lower vertebrae.

The increasing obese population, high prevalence of spinal cord injuries (SCI), and increasing geriatric population are expected to enhance the market growth. However, the stringent regulatory policies, lack of awareness for the use of advanced technologies, and product recalls are projected to curb the growth of the market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5657

Segment Analysis

The global thoracolumbar spine devices market, by product type, has been segmented into spinal implants, devices and instrumentation, and spine biologics. Based on type of surgery, the Thoracolumbar spine devices market has been categorized as open surgery and minimally invasive surgery (MIS). The by material segment is further segmented as titanium, stainless steel, biomaterials, and others. Based on end user, the thoracolumbar spine devices market has been categorized as hospitals and clinics, ambulatory surgery centers, academic institutes and research centers, and others.

Regional Analysis

The Global Thoracolumbar Spine Devices Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The existence of medical device companies, developed healthcare infrastructure, significant per capita healthcare spending, high funding for research & development projects, focused researches in spine disorders along with grants from government healthcare agencies, and high adoption of advanced medical technologies in the US and Canada are likely to support the dominance of the Americas during the forecast period.

Europe is anticipated to account for the second-largest market share during the forecast period. The market growth in Europe can be attributed to factors such as the increasing number of individuals affected by spinal cord injuries. For instance, according to the Association for Spinal Injury Research, Rehabilitation, and Reintegration, the number of people diagnosed with a spinal cord injury in the UK is 2500 per year.

Asia-Pacific is likely to be the fastest-growing region in the global thoracolumbar spine devices market. The growing geriatric population and booming medical tourism sector in India, China, Australia, and Malaysia are likely to impact the regional market growth during the forecast period. According to the United Nations Department of Economic and Social Affairs (UN DESA), in 2017, 12% of the population in Asia and 17% in Oceania was aged 60 or above, which is projected to increase to 24% and 23%, respectively by 2050. This elderly population is more prone to develop thoracolumbar spine disorders, which are fostering market growth. India held a share of 16.2% in the Asia-Pacific thoracolumbar spine devices market in 2018.

The Middle East & Africa market is projected to show gradual growth during the forecast period. In this region, the Middle East is anticipated to dominate owing to factors like increasing growth in the medical tourism sector. For instance, according to the Dubai Health Authority (DHA), in 2016, the medical tourism sector showed a significant growth of 9% to 10%, and more than 326,649 patients from all over the world visited Dubai for medical treatments.

Market Players

MRFR recognizes the following companies as the Key Players in the Global Thoracolumbar Spine Devices Market—Orthofix Holdings, Inc. (US), Alphatech holdings, Inc. (US), B. Braun Melsungen AG (Germany), Depuy Synthes (US), Exactech, Inc. (US), Globus Medical, Inc. (US), Medtronic Plc (Ireland), NuVasive, Inc. (US), ZIMMER BIOMET HOLDINGS, INC. (US), and STRYKER CORPORATION (US).

Key Findings of the Study

·The Global Thoracolumbar Spine Devices Market was valued at USD 6,531.2 million in 2018 and is estimated to grow to USD 8,484.7 Million by 2025 at a CAGR of 3.72% during the assessment period

·The Americas accounted for the largest share of the global market due to the presence of key market players, sophisticated healthcare infrastructure, and increasing R&D in the field of thoracolumbar spine devices.

·Based on product type, the spine biologics segment accounted for a market share of 23.5% in 2018

·On the basis of the end user, the hospitals and clinics segment dominated the market and accounted for a share of 48.7% in 2018

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/thoracolumbar-spine-devices-market-5657

Worldwide PEGylated Drugs Market Top 10 Players Universal Analysis, Industry Demand And 2025 Forecast

 PEGylated Drugs Market is expected to register a CAGR of 5.53% to reach USD 13,503.67 Million by 2025.

PEGylation refers to the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to bioactive molecules (proteins, peptides, enzymes, antibody fragments, oligonucleotides, etc.). It is a promising technique to increase the therapeutic efficacy of medicines in clinical settings. Several PEGylated drugs have been approved by the Food and Drug Administration (FDA), and many drugs are being tested in clinical settings.

The major companies are rigorously investing in R&D of PEGylated drugs and have a good number of molecules in the pipeline. For instance, UCB and Biogen are evaluating the safety and efficacy of dapirolizumab pegol. Dapirolizumab pegol is an anti-CD40L pegylated Fab and is in Phase 2b of the clinical trial. The drug is being developed for the treatment of systemic lupus erythematosus.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8436 

However, adverse reactions associated with PEGylated drugs and drug recalls are anticipated to restrain the growth of the global PEGylated drugs market during the forecast period.

Market Dynamics

The Global PEGylated Drugs Market is emerging due to the increase in the prevalence of chronic diseases such as cancer, growing pharmaceutical industry, and advancements in the biologics sector. For instance, according to the National Cancer Institute, in 2016, 15.5 million new cases of cancer were registered, and approximately USD 147.3 billion were spent for cancer care in the US. This rising prevalence of cancer is creating a demand for effective drugs. The use of advanced drug delivery system with PEGylation technology is significant in the field of anti-cancer therapy as PEGylating enhances retention time of therapeutics which in turn is expected to boost the growth of the global PEGylated drugs market.

Segmentation

The Global PEGylated Drugs Market has been segmented into molecule, indication, and region.

On the basis of molecule, the global PEGylated drugs market has been segmented into protein, enzyme, aptamer, antigen-binding fragment (FAB’ fragment) and others. PEGylated protein is estimated to account for the largest market share of 64.80% during the forecast period. Rising demand for PEGylation, increase in a number of chronic diseases including cancer, and product launches by major market players are propelling the growth of this segment. For instance, in 2018, Coherus Biosciences has gained FDA approval for its Pegfilgrastim biosimilar, Udenyca (Pegfilgrastim-cbqv). Udenyca is a leukocyte growth factor used to decrease the incidence of infection in patients with non-myeloid malignancies.

On the basis of indication, the Global PEGylated Drugs Market has been segregated into cancer, hemophilia, hepatitis, gout, and others.

Regional Analysis

The Global PEGylated Drugs Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas accounted for a market share of 65.73% in 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada.

Europe was the second-largest Global PEGylated Drugs Market in 2018. The rising efforts by the government to reduce chronic disease burden owing to the rising occurrence of cancer in the region is projected to drive the market growth. The Europe region is further segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries has been, segmented into Germany, the UK, France, Italy, Spain, and the rest of Western Europe.

The Asia-Pacific region has been categorized as China, India, Japan, Australia, South Korea and the rest of Asia-Pacific. It holds the third-largest position in the PEGylated drugs market.

The Middle East & Africa is expected to witness a remarkable growth owing to the increasing applications PEGylated drugs for the treatment of chronic diseases.

Prominent Players

The Prominent Players in the Global PEGylated Drugs Market Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Bayer AG. The players operating in the global PEGylated Drugs Market are focusing on product launches, along with expanding their global footprints by entering untapped markets.    

FOR MORE DETAILS – @ https://www.marketresearchfuture.com/reports/pegylated-drugs-market-8436 

Metabolomics Services Market Swot Analysis, Major Key Players Revenue, Analysis And Forecasts To 2025

 Market Highlights

Metabolomics Services Market is expected to register a CAGR of 7.77%% during the forecast period with a market value of USD 16,291.0 Million till 2025.

Metabolomics services have been growing at a rapid pace over the last few years. Metabolomics services provide information about the metabolic phenotype by identifying and quantifying the biochemical byproducts of metabolism using different technologically advanced products.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8435

The major key factors driving the market growth are the growing prevalence of diseases such as cancer, neurological disorders, and cardiac diseases across the globe, technological advancements in instrumentation, and increasing application of metabolomics in the life science and biotechnological industry. However, factors such as high cost of instruments and stringent government policies/regulations may hamper the market growth. 

Segment Analysis

The Global Metabolomics Services Market is segmented into product and service and application. Based on product and service, the market has been segmented into chromatography, metabolomics bioinformatics services, and mass spectrometry. On the basis of application, the global metabolomics services market has been segmented into biomedical and pharmaceutical, agriculture, and food.

Regional Analysis

The Global Metabolomics Services Market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas are expected to hold the largest share of the global metabolomics services market. This is owing to the increasing patient population suffering from cancer, and cardiovascular diseases are boosting the market growth in this region.

The Europe market holds the second-largest position in the global metabolomics services market due to the presence of a large number of companies such as Biocrates Life Sciences AG (Biocrates), Bruker, Waters, and other providing metabolomics services drives the growth of the market in this region.

Asia-Pacific is estimated to be the fastest-growing region owing to a large number of patient population suffering from chronic disease and increasing demand for treatment for the same.  

The metabolomics services market in the Middle East & Africa accounts for the least market share due to the adequate healthcare infrastructure support accounted for a relatively smaller market share in 2018.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Metabolomics Services Market—Agilent Technologies, Inc. (US), Waters (US), Bruker (US), TMIC (CANADA), Thermo Fisher Scientific (US), Biocrates Life Sciences AG (AUSTRIA), Creative Proteomics (US), Human Metabolome Technologies America Inc (JAPAN), Shimazdu Corporation (Japan), and Metabolon, INC (US)

Key Findings of the Study

• The Global Metabolomics Services Market was valued at USD 9,729.0 million in 2018, is estimated to grow at USD 16,291.0 Million by 2025 at a CAGR of 7.77%% during the assessment period
• America accounted for the largest share of the global market due to the presence of a huge patient population suffering from chronic diseases.
• Based on application, the biomedical and pharmaceutical segment accounted for the largest market share in 2018

FOR MORE DETAILS – @ https://www.marketresearchfuture.com/reports/metabolomics-services-market-8435 

Worldwide Pain Relief Medication Market 2020 Synopsis With Leading Players, Industry Growth Factor Foresight By 2025

 Market Highlights

According to MRFR analysis, Pain Relief Medication Market  is expected to register a CAGR of 4.73% during the forecast period of 2019 to 2025 and held a value of USD 55,275 million in 2018.

Pain relief medicine is a branch of medicine that employs an interdisciplinary approach for easing the suffering and improving the quality of life of those living with acute as well as chronic pain.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8431

The growth of the global pain relief medication market is driven by several factors such as increasing patient population suffering from chronic pain and cancer pain, increasing research in the pain management field, and rising product launch in the pain relief medication market. However, the stringent regulations and high cost of drugs are likely to hamper the growth of the global pain relief medication market.

Several market players currently dominate the global pain relief medication market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in July 2018, AbbVie received approval for Orilissa (elagolix) from the US Food and Drug Administration (FDA) for the management of moderate to severe pain associated with endometriosis.

Segmentation

The global pain relief medication market has been segmented based on drug class, indication, and distribution channel.

The market, based on drug class, has been divided into nonsteroidal anti-inflammatory drugs, opioids, COX-2 inhibitors, and others. The nonsteroidal anti-inflammatory drug segment is likely to be the largest during the review period due to the high efficacy rate of this drug class. The opioids segment is predicted to be the fastest-growing due to the increasing awareness about the drugs in this class in the pain relief medication market.

The global pain relief medication market has been segmented based on the indication, into cancer pain, neuropathic pain, musculoskeletal pain, inflammatory conditions, and others. The cancer pain segment is expected to hold the majority share of the market owing to the increasing people suffering from this type of pain. The neuropathic pain segment is expected to be the fastest-growing due to the rising patient population in different economies.

The global pain relief medication market, by distribution channel, has been divided into hospital and retail pharmacies, and online pharmacies. The hospitals and retail pharmacies segment is projected to hold the largest share of the market due to the increasing number of hospital in-visits. The online pharmacies segment is expected to be the fastest growing owing to the rise in the awareness about online distribution network.

Key Players

Some of the key players in the global pain relief medication market are AbbVie Inc. (US), Allergan plc (Ireland), Astellas Pharma Inc. (Japan), Bayer (Germany), Biogen Idec (US), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb (US), Eli Lilly and Company (US), GlaxoSmithKline (UK), Mallinckrodt Pharmaceuticals (UK), Pfizer, Inc. (US), Purdue Pharma (US), Sanofi (France), and Teva Pharmaceutical Industries Ltd (Israel).

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are expected to be the largest market owing to the rise in chronic diseases in this region. In Brazil, chronic pain is a widespread clinical condition, affecting between 28% and 41% of the Brazilian population. The pain relief medication market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European pain relief medication market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The pain relief medication market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the rise in initiatives by public and private organizations, the market in Asia-Pacific is expected to be the fastest-growing. The pain relief medication market in the Middle East & Africa has been divided into the Middle East and Africa.

FOR MORE DETAILS – @ https://www.marketresearchfuture.com/reports/pain-relief-medication-market-8431 

Global Perfusion Radiology Market Solid Segment Analyzed By Latest Trends, Growth Rate And 2025 Insight

 Market Highlights

The Global Perfusion Radiology Market is expected to register a CAGR of 7.48% during the forecast period, with a market value of USD 9,858 Million till 2025. Perfusion is the passage of fluid through the lymphatic system to organs or tissues. Perfusion radiology is the process by which passage of perfusion can be observed, recorded, and quantified. This is widely used for the diagnosis of chronic disorders such as cancer, brain tumor, and lung-related disorders.

The growing prevalence of cardiovascular and neurological diseases, increasing geriatric population, and advancements in technology are expected to enhance market growth. However, the stringent regulatory policies and lack of awareness for the use of advanced technologies are projected to curb the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8419

Segment Analysis

The Global Perfusion Radiology Market, by application, has been segmented into cardiovascular imaging, ventilation imaging, brain imaging, and others. By end-user, the global perfusion radiology market has been classified as hospitals, diagnostic centers, and others. 

Regional Analysis

The Global Perfusion Radiology Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

North America accounted for the largest market share of in 2018, owing to the incidence of cardiovascular diseases, brain tumors, and tumor-related angiogenesis

Europe is anticipated to account for the second-largest market share during the forecast period. The market growth in Europe can be attributed to the considerable rise in neurological disorders. For instance, according to the European Brain Council, 2017 data, a total of 220.7 million people in Europe were suffering from at least one neurological disease, which promoted the use of perfusion radiology for the diagnosis of such diseases.

Asia-Pacific is likely to be the fastest-growing region in the global perfusion radiology market. The high growth rate is due to owing to the presence of rapidly developing economies of China, India, and South Korea. India held a share of 18.8% in the Asia-Pacific perfusion radiology market in 2018.

The Middle East & Africa market is projected to show gradual growth during the forecast period. In this region, the Middle East is anticipated to dominate owing to the presence of developed countries such as Egypt, Saudi Arabia, and others.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Perfusion Radiology Market— GE Healthcare (US), Siemens Healthineers AG (Germany), Canon Medical Systems Corporation (Japan), Bracco Diagnostic, Inc. (Italy), Koninklijke Philips N.V. (Netherlands), Shimadzu Corporation (Japan), Lantheus Medical Imaging, Inc (US), Perimed (US), Neusoft Corporation (China), and Advantis Medical Imaging (Netherlands)

Key Findings of the Study

• The Global Perfusion Radiology Market was valued at USD 6,009.3 million in 2018 and is estimated to grow to USD 9,858 Million by 2025 at a CAGR of 7.48% during the assessment period
• The Americas accounted for the largest share of the global market due to the increase in the incidence of cardiovascular diseases, brain tumors, and tumor-related angiogenesis.
• Based on application, the cardiovascular imaging segment accounted for a market share of 12% in 2018
• On the basis of the end-user, the hospital’s segment dominated the market and accounted for a share of 65% in 2018

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/perfusion-radiology-market-8419

Global Flat Panel Detector Market Solid Segment Analyzed By Latest Trends, Growth Rate And 2024 Insight

 Market Highlights

The global flat panel detector (FPD) market held a market value of USD 3.06 Billion in 2018 and is projected to grow at a CAGR of 6.7% over the forecast period.  

Flat panel detector (FPD) is a type of solid-state X-ray digital radiography device. It works in the same way as image sensors used in digital photography and video works. Growing public and private investments in digital imaging technologies and declining prices and benefits offered by digital detectors are positively affecting market growth. Additionally, growing medical tourism in developing countries is also expected to drive the market growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7903 

On the other hand, the high cost of the system is likely to hamper the growth of the market.

Segmentation

The global flat panel detector (FPD) market has been segmented by portability, application, and end user.

By portability, the market has been segmented into fixed and portable. The portable flat panel detector is expected to show the largest market share.

By application, the market has been segmented into medical, orthopedic, cardiac, veterinary, mammogram, dental, and others.

The market, by end user, has been segmented into hospitals and clinics, and diagnostic centers.

Key Players

Some of the prominent players in the global flat panel detector (FPD) market are General Electric Company, Carestream Health, Canon Medical Systems Corporation, Fujifilm Holdings America Corporation, PerkinElmer Inc., Trixell, iRay Technology, Varian Medical Systems, Inc., Agfa-Gevaert Group, New Medical Imaging Co., Ltd, Varex Imaging Corporation, Imaging Dynamics Company Ltd and others.

Regional Analysis

On a regional basis, the Americas is anticipated to dominate the global flat panel detector (FPD) market owing to the technological innovations, increasing healthcare spending, availability of venture capital and government funding, and increasing incidence of chronic diseases in the region has fueled the growth of the market. Additionally, major companies are located in North America which is fueling the market growth.

Europe is expected to hold the second largest position in the global flat panel detector (FPD) market owing to the presence of well-developed healthcare sector, strong government support for research & development and high healthcare expenditure in the European countries. Well-developed technologies in Europe have also played a predominant role in the development of the European market.

Asia-Pacific is anticipated to be the fastest growing region in the global flat panel detector (FPD) market owing to the growing adoption of digital imaging systems, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.

The Middle East & Africa has the least share of the global flat panel detector (FPD) market.  Moreover, the major market share of the region is expected to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/flat-panel-detector-market-7903

Global Autoinjectors Market Positive Growth And Forecasts By 2024

 Market Highlights

The Global Autoinjectors Market is Estimated to be Valued at USD 79,741 Million by 2024 and is Expected to Register a CAGR of 17.42% During the Forecast Period.

The disposable autoinjectors segment is expected to lead the market and register a substantial CAGR to reach USD 53,696.20 Million by the end of 2024. The increasing demand for testing new drugs and chemicals and vigorous growth in the pharmaceutical and biopharmaceutical sectors are expected to drive the market growth. Additionally, the disposable autoinjectors segment is also projected to exhibit the highest CAGR of 17.90% from 2019 to 2024.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6311 

Americas accounted for the largest market share of 40.6% in 2018, and the regional market is projected to register a CAGR of 16.60% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Indian market is projected to exhibit the highest growth rate of 18.95% during the forecast period of 2019 to 2024. 

Segment Analysis

The Global Autoinjectors Market has been segmented on the basis of product type, design therapeutic application, distribution channel, and region. On the basis of product type, the market has been divided into the disposable autoinjectors and reusable autoinjectors. The disposable autoinjectors segment held the majority market share in 2018. It also was the fastest-growing owing to the increasing demand for testing new drugs and chemicals and vigorous growth in the pharmaceutical and biopharmaceutical sectors.

Market Players

Market Research Future (MRFR) recognizes Amgen Inc. (US), Becton, Dickinson and Company (US), AbbVie Inc. (US), Mylan N.V. (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Owen Mumford Ltd (UK), Consort Medical (UK), SHL Group (Taiwan), Johnson & Johnson Services Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), Antares Pharma (US) as the key players in the Global Autoinjectors Market.

Regional Analysis

Geographically, the global autoinjectors market has been segmented into North America, Europe, Asia-Pacific, and the Middle East & Africa. As per MRFR analysis, the Americas was the largest market for the autoinjectors in 2018 and is expected to remain dominant during the review period. Europe accounted for a significant market share and is projected to be the second-largest market during the forecast period. The well-established healthcare infrastructure, technology advancement, and innovation in drug delivery systems, and rising prevalence of anaphylaxis incidences, diabetes, and cancer are driving the growth of the autoinjectors market in the region. Germany accounted for the largest market share of 24.7% in 2018, and the country-level market is projected to register a CAGR of 15.84% during the forecast period.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/autoinjectors-market-6311